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Clopidogrel Responsiveness Regardless
of the Discontinuation Date Predicts
Increased Blood Loss and Transfusion Requirement
After Off-Pump Coronary Artery Bypass Graft Surgery
Young-Lan Kwak, MD, PHD,*† Jong-Chan Kim, MD,* Yong-Seon Choi, MD,*
Kyung-Jong Yoo, MD, PHD,‡ Young Song, MD,* Jae-Kwang Shim, MD, PHD*
Seoul, South Korea
Objectives The purpose of this study was to evaluate the association of the percentage of platelet inhibitory response to
clopidogrel as assessed by modified thromboelastography with bleeding and transfusion requirement after off-
pump coronary artery bypass graft (OPCABG) surgery.
Background Interindividual variability of clopidogrel responsiveness may influence bleeding and transfusion requirement.
Methods One hundred patients who received clopidogrel within 5 days of OPCABG were prospectively enrolled. The pri-
mary end point was to compare post-operative bleeding and transfusion requirement in relation to the tertile
distribution of the percentage of platelet inhibitory response to clopidogrel.
Results Blood loss in the patients in the third tertile was 914  264 ml compared with 623  249 ml in those in the
first and 683  254 ml in those in the second tertiles (p  0.001). Significantly more patients in the third tertile
were transfused, and the number of units transfused was also larger. On multivariate analysis, the third tertile
was associated with an 11-fold increased risk of transfusion (95% confidence interval: 2.77 to 47.30, p 
0.001). The optimal cutoff value for the transfusion requirement measured by receiver-operator characteristic
curve analysis was 70% platelet inhibitory response to clopidogrel (area under the curve: 0.771; 95% confidence
interval: 0.674 to 0.868; p  0.001).
Conclusions A high percentage of platelet inhibitory response to clopidogrel, regardless of the proximity of clopidogrel expo-
sure, predicts increased blood loss and transfusion requirement after OPCABG with a cutoff value of 70% for
increased risk of transfusion. These findings might implicate a potential role of modified thromboelastography in
deciding the timing of OPCABG in patients who need continued clopidogrel therapy. (J Am Coll Cardiol 2010;
56:1994–2002) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.108o
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ts dual antiplatelet therapy with aspirin and clopidogrel has
ecome the cornerstone of the management of patients with
oronary artery disease (1,2), an increasing number of
atients undergoing coronary artery bypass graft (CABG)
re at risk of irreversible platelet inhibition. Consequently,
oncerns for increased hemorrhagic complications after
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010, accepted March 30, 2010.n-pump CABG have led to recommendations to stop the
edications 5 days before elective surgery (3–5).
See page 2003
In view of post-operative blood loss, cardiopulmonary
ypass has deleterious effects on the coagulation system and
ff-pump coronary artery bypass graft (OPCABG) has been
roposed as an alternative surgical technique to reduce the
isk of transfusion requirement in patients with recent
xposure to antiplatelet therapy, but with conflicting results
6–9). This inconsistency may be attributable to the pres-
nce of substantial interindividual variability of clopidogrel
esponsiveness, which has not been considered previously in
he surgical setting (10,11). Accordingly, the timing of surgery
hould be decided based on more objective findings encom-
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December 7, 2010:1994–2002 Clopidogrel Responsiveness and Bleeding in OPCABG Surgeryassing the individual variability of clopidogrel responsiveness
nd balancing the bleeding risk with the ischemic benefit.
For that purpose, platelet function assays have been used
ith prospective studies demonstrating close correlation be-
ween decreased clopidogrel responsiveness and increased isch-
mic complications after percutaneous coronary intervention
12–14). However, no comprehensive data exist with regard to
he association of increased bleeding and transfusion require-
ent with clopidogrel responsiveness after OPCABG.
We hypothesized that patients with recent exposure to
lopidogrel undergoing OPCABG who display a high
ercentage of inhibitory response to clopidogrel as as-
essed by thromboelastography (TEG) platelet mapping
ssay (Haemoscope Corp., Niles, Illinois), regardless of
he discontinuation date, are at increased risk of post-
perative bleeding and the need for transfusion.
ethods
fter institutional review board approval and informed
onsent were obtained, patients scheduled for isolated mul-
ivessel OPCABG between December 2007 and March
009 were prospectively studied. The exclusion criteria were
mergency (operation priority, including emergent or sal-
age OPCABG), myocardial infarction, history of cardiac
urgery, history of bleeding diathesis or hepatic dysfunction,
eft ventricular ejection fraction 40%, hematocrit 33%,
latelet count 100,000 mm3, abnormal range of pro-
hrombin time and activated partial thromboplastin time,
reatinine 1.4 mg/dl, and use of glycoprotein IIb/IIIa
nhibitors (Fig. 1).
A total of 100 patients who were taking a daily oral
egimen of aspirin 100 mg and clopidogrel 75 mg for at
east 1 week were enrolled. The patients were divided
nto groups according to the discontinuation date of the
ual antiplatelet therapy: aspirin and clopidogrel contin-
ed until 1 day before the surgery (n  50) and until 3
ays before the surgery (n  50). The subdivision at 3
ays before the surgery was according to the rate of
latelet function recovery (15) and the results of previous
tudies performed during OPCABG (6,7).
Perioperative management of patients was according to
nstitutional standards by a single team of anesthesiologists
nd cardiothoracic surgeons who were blinded to TEG
latelet mapping assay results.
All surgical procedures were performed by 1 surgeon
hrough a median sternotomy, and the heart was dis-
laced using a posterior pericardial stitch, large (12  70
m) gauze swabs, and tissue stabilizer (Octopus Tissue
tabilization System, Medtronic Inc., Minneapolis, Min-
esota). Systemic heparinization during anastomoses was
chieved with 150 U/kg of porcine heparin, with addi-
ional doses given to reach the target activated clotting
ime of 300 s. On the completion of anastomoses,
eparin activity was neutralized with protamine sulfate
0.5 mg/150 U of heparin). A cell salvage device was used guring the surgery in all cases,
nd salvaged blood was rein-
used in the patient before the
nd of the surgery. None of the
atients received aprotinin or
ntifibrinolytics throughout the
tudy period. All patients were
ransferred to the intensive care
nit after the surgery.
Allogeneic packed red blood
ells were transfused when the
ematocrit level was 24% throughout the study period.
resh frozen plasma was transfused when the post-
perative international normalization ratio was 1.5
ith excessive bleeding of 200 ml/h for 2 consecutive
ours. The criteria for transfusion of platelets were
ost-operative platelet count 50,000/mm3 with exces-
ive bleeding of 200 ml/h for 2 consecutive hours.
urgical re-exploration was indicated when chest tube
rainage was 200 ml/h for 6 consecutive hours or 400
l during the first hour despite normalized activated
lotting time and global coagulation status.
The hematocrit level, platelet counts, prothrombin
ime, and activated partial thromboplastin time were
easured 24 h before and after the surgery. The total
umber of units of packed red blood cells, fresh frozen
lasma, and platelets given during the post-operative
ospitalization period were recorded, including the num-
er of units given during the operation and in the
ntensive care unit post-operatively. Intraoperative blood
oss was recorded as the amount of blood collected by a
ell salvage device that was processed and reinfused.
ost-operative blood loss was recorded as the volume of
hest and mediastinal tube drainage measured 24 h after
urgery and the drained blood was not reinfused. Dual
ntiplatelet therapy consisting of aspirin 100 mg and
lopidogrel 75 mg was started 24 h after the surgery as
dequate.
rimary end points. The amount of post-operative blood
oss and transfusion requirement were compared in rela-
ion to the tertile distribution of the percentage of
latelet inhibitory response to clopidogrel measured by
EG platelet mapping assay. Blood sampling and TEG
latelet mapping assay were performed immediately be-
ore the induction of anesthesia according to the manu-
acturer’s recommendation, which are as follows. One
illiliter of heparinized blood was transferred to a vial
ontaining kaolin and mixed by inversion. Five hundred
icroliters of the activated blood were then transferred to
vial containing heparinase and mixed to neutralize the
eparin. The neutralized blood (360 l) was added to a
eparinase-coated cup and assayed in the TEG analyzer
o measure the thrombin-induced clot strength. Hepa-
inized blood (340 l) was added to a noncoated cup
ontaining reptilase and activator F (factor XIIIa) to
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
OPCABG  off-pump
coronary artery bypass
graft
TEG 
thromboelastographyenerate a whole-blood cross-linked clot in the absence
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Clopidogrel Responsiveness and Bleeding in OPCABG Surgery December 7, 2010:1994–2002Figure 1 Flowchart Demonstrating Patient Enrollment According to Inclusion Criteria
A total of 311 eligible patients who received a daily oral regimen of aspirin 100 mg and clopidogrel 75 mg for at least 1 week until within 5 days of surgery were pro-
spectively enrolled between December 2007 and March 2009. After carefully selecting the patients according to inclusion criteria, 100 patients were finally included in
the study.
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December 7, 2010:1994–2002 Clopidogrel Responsiveness and Bleeding in OPCABG Surgeryf thrombin generation or platelet stimulation. A third
ample (340 l) of heparinized blood was added to a
onheparinase-coated cup in the presence of the activator
and adenosine diphosphate (2 mol) or arachidonic
cid (1 mmol/l) to generate a whole-blood cross-linked
lot with platelet activation. The surgeon and anesthesi-
logists involved in patient management were blinded to
he results of the TEG platelet mapping assay.
econdary end points. Evaluation of risk factors for the
eed for transfusion including the percentage of platelet
nhibitory responses to the antiplatelet agents and discon-
inuation date was performed. In addition, the evaluation of
major morbidity end points and 30-day incidence of major
dverse cardiac events was performed. The major morbidity
nd points were defined as permanent disability caused by
troke, renal dysfunction, any cardiac reoperation, pro-
onged ventilation 48 h, and deep sternal wound infection
16). For clarification, renal dysfunction was defined as
cute post-operative renal insufficiency resulting in 1 of
he following: an increase of serum creatinine to 2.0
g/dl; at least a 50% greater increase in creatinine above the
aseline pre-operative value; and a new need for dialysis.
ajor adverse cardiac events were defined as cardiac death,
yocardial infarction, and revascularization. Post-operative
yocardial infarction was defined as the occurrence of an
ncrease in troponin-T0.5 ng/ml (5 times the upper normal
imit) and/or development of new pathologic Q-wave on the
lectrocardiogram (17). Troponin T was evaluated 1 day before
urgery and 12, 24, and 48 h after surgery.
tatistical analysis. Statistical analyses were performed
sing SPSS version 13.0 (SPSS Inc., Chicago, Illinois). We
etermined that 84 patients would be required to detect a
50-ml difference in post-operative blood loss among the
ertile of clopidogrel responsiveness with a standard devia-
ion of 300 ml or 93 patients to detect a 2-fold increase in
he incidence of transfusion requirement in the third tertile
onsidering that 40% of the patients with similar character-
stics required transfusion after OPCABG at an alpha level
f 0.05 with 80% power (7).
Continuous variables among the tertiles were compared
y 1-way analysis of variance with Bonferroni post-hoc test.
ontinuous variables between the patients who were trans-
used or not were compared by the t test for normally
istributed values; otherwise, the Mann-Whitney U test was
sed. Proportions were compared by the Fisher exact test or
hi-square test as appropriate. The odds ratios and 95%
onfidence intervals investigating the independent predic-
ive role of the percentage of platelet inhibitory responses to
ntiplatelet agents assessed by TEG platelet mapping assay
n the transfusion requirement were assessed by logistic
egression. The following parameters were first evaluated in
he univariate model: age, female sex, pre-operative hemat-
crit, left main disease, discontinuation date of the anti-
latelet agents, tertile distribution of platelet inhibitory
esponse, and variables with p  0.2 between patients who
equired transfusion or not. Only variables with p  0.2 rere then entered into the final model of multivariable
ogistic regression analysis. The ability of the TEG platelet
apping assay to discriminate patients who required trans-
usion or not was evaluated by receiver-operator character-
stic curve analysis. The optimal cutoff value was defined as
he point of the percentage of platelet inhibitory response
roviding the greatest sum of sensitivity and specificity.
ategorical variables are expressed as number (%) and
ontinuous variables are expressed as mean  SD, with p 
.05 considered statistically significant.
esults
PCABG could be successfully performed in all 100
atients without emergent conversion to on-pump CABG.
emostatic re-exploration due to excessive bleeding was
erformed in 1 patient who had received clopidogrel therapy
ntil the day before surgery. However, an obvious surgical
leeder was found, and thus data for this patient were
xcluded from statistical analyses.
Patient characteristics including the number of patients
ho stopped clopidogrel 1 day before surgery and the
ercentage of platelet inhibitory response to aspirin were all
imilar in relation to tertile distribution of the percentage of
latelet inhibitory response to clopidogrel (Table 1).
In the perioperative data, patients in the third tertile had
significantly greater amount of post-operative blood loss
han those of the first and second tertiles. In addition,
ignificantly more patients in the third tertile required
acked red blood cells and fresh frozen plasma transfusion,
nd the number of units transfused was also significantly
igher in patients in the third tertile than those in the first
ertile (Table 2). Platelets were transfused in 2 patients each
n the second and third tertiles during the post-operative
eriod, and 6 U were transfused in each patient. Linear
egression analysis between the percentage of platelet inhib-
tory response to clopidogrel and aspirin with post-operative
lood loss resulted in R2 values of 0.238 and 0.015,
espectively.
Changes in troponin T and incidents of major adverse
ardiac events and morbidity end points were similar in all
ertiles except for the length of post-operative hospitaliza-
ion, which was significantly longer in patients in the third
ertile compared with those in the first and second tertiles
Table 3).
In comparisons of patients who were transfused and those
ho were not (Table 4), the discontinuation date of clopi-
ogrel, the number of grafts performed, and the percentage
f the platelet inhibitory response to clopidogrel met the
redefined criterion of p  0.2 and were further analyzed
ith logistic regression analysis with the previously cited
isk factors for transfusion described in the Methods sec-
ion. In univariate analysis of predictors of transfusion
equirement, the discontinuation date of clopidogrel, tertile
istribution of the percentage of the platelet inhibitory
esponse, and the number of grafts performed had a p value

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Clopidogrel Responsiveness and Bleeding in OPCABG Surgery December 7, 2010:1994–20020.2. In multivariate analysis of these variables, only the
ighest tertile of the percentage of the platelet inhibitory
esponse to clopidogrel remained an independent risk factor
Table 5).
atient Characteristics in Relation to Tertile Distribution of the PeTable 1 Patient Characteristics in Relation to Tertile Distributi
Total
(n  99)
Fir
(15.
Age, yrs 65 7
Female sex 28 (28)
Body surface area, m2 1.7 0.1 1
Pre-operative medication
Beta-blockers 76 (77)
Renin-angiotensin system antagonists 36 (36)
Calcium-channel blockers 59 (60)
Statins 72 (73)
Hypertension 64 (65)
Diabetes mellitus 41 (41)
Left ventricular ejection fraction, % 62 9
Left main disease 31 (31)
Clopidogrel stopped 1 day before surgery 49 (50)
TEG parameters
% inhibitory response to clopidogrel 58 26
% inhibitory response to aspirin 69 21
Maximal amplitude, mm 61.5 5.8 60
Laboratory data
Creatinine, mg/dl 1.0 0.2 1
Hematocrit, % 40 3
Platelet count, 103/mm2 258 54 2
Prothrombin time, s 11.3 0.7 11
Activated partial thromboplastin time, s 31.5 3.2 30
alues are mean  SD or n (%) of patients. Tertiles were established for the percentage of platele
ange for maximal amplitude is 54 to 72 mm.
erioperative Data in Relation to Tertile Distribution of the PercentTable 2 Perioperative Data in Relation to Tertile Distribution of
Total
(n  99)
Fir
(15.
Operation time, min 270 48 26
Total graft reconstruction time, min 33 9 3
No. of grafts performed 3.4 0.7 3
Intraoperative
Blood loss, ml 234 151 18
No. of patients transfused with pRBCs 6 (6)
pRBC transfusion, U 0.1 0.3 0
Post-operative
Blood loss 24 h, ml* 740 283 62
No. of patients transfused with pRBCs* 27 (27)
pRBC transfusion, U* 0.4 0.8 0
No. of patients transfused with FFP* 11 (12)
FFP transfusion, U* 0.4 1.1 0
Post-operative laboratory data
Hematocrit, % 28 2 2
Platelet count, 103/mm2 173 43 17
Prothrombin time, s 13.2 1.1 13
Activated partial thromboplastin time, s 34.9 6.0 35alues are mean  SD or n (%). *p  0.05.
FFP  fresh frozen plasma; pRBC(s)  packed red blood cell(s).In the receiver-operator characteristic curve analysis, the
ercentage of the platelet inhibitory response to clopidogrel
emonstrated an area under curve of 0.771 with a p value
0.001 and a 95% confidence interval of 0.674 to 0.868.
age of Platelet Inhibitory Response to Clopidogrelthe Percentage of Platelet Inhibitory Response to Clopidogrel
tile
.4%)
Second Tertile
(43.6%–75.9%)
Third Tertile
(76.5%–100%) p Value
65 6 65 7 0.989
) 9 (27) 7 (21) 0.174
.1 1.7 0.1 1.7 0.1 0.564
) 25 (76) 24 (73) 0.384
) 12 (36) 9 (27) 0.127
) 20 (61) 22 (67) 0.212
) 23 (70) 24 (73) 0.783
) 19 (58) 21 (64) 0.442
) 15 (46) 12 (36) 0.619
0 61 10 62 7 0.573
) 12 (36) 10 (30) 0.792
) 12 (36) 21 (64) 0.221
1 59 10 87 8 0.001
1 67 21 74 16 0.381
.4 62.5 5.4 61.6 5.4 0.337
.2 1.0 0.2 1.0 0.1 0.731
40 3 40 4 0.292
7 257 51 251 43 0.571
.7 11.5 0.7 11.2 0.7 0.302
.2 32.1 3.6 31.6 2.6 0.165
tory response to clopidogrel measured by thromboelastography (TEG) mapping assay. Reference
of Platelet Inhibitory Response to ClopidogrelPercentage of Platelet Inhibitory Response to Clopidogrel
tile
.4%)
Second Tertile
(43.6%–75.9%)
Third Tertile
(76.5%–100%) p Value
6 275 56 268 42 0.712
33 10 33 10 0.922
.8 3.4 0.7 3.4 0.7 0.881
8 261 183 251 160 0.110
3 (9) 2 (6) 0.608
.2 0.1 0.3 0.1 0.4 0.751
49 683 254 914 264 0.001
7 (21) 17 (51) 0.001
.3 0.4 0.9 0.7 0.9 0.003
3 (9) 7 (21) 0.019
.2 0.3 0.8 0.7 0.9 0.034
28 2 28 3 0.508
3 166 40 176 46 0.566
.0 13.6 1.1 13.0 1.1 0.116
.5 35.1 6.0 34.4 5.5 0.828rcenton of
st Ter
0%–43
65 7
12 (36
.7 0
27 (82
15 (46
17 (52
25 (76
24 (73
14 (42
63 1
9 (27
16 (49
29 1
69 2
.4 6
.0 0
39 3
65 6
.3 0
.6 3agethe
st Ter
0%–43
6 4
2 8
.5 0
9 8
1 (3)
.1 0
3 2
3 (9)
.1 0
1 (3)
.1 0
8 2
6 4
.2 1
.2 6
T
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December 7, 2010:1994–2002 Clopidogrel Responsiveness and Bleeding in OPCABG Surgeryhe optimal cutoff value for post-operative transfusion
equirement was 70% platelet inhibitory response to clopi-
ogrel with a sensitivity and specificity of 77.8% and 75.0%,
espectively (Fig. 2).
iscussion
his prospective, observational study demonstrates that
atients with recent exposure to dual antiplatelet therapy
ho exhibited an increased percentage of platelet inhibitory
esponse to clopidogrel, constituting the third tertile, were
hanges in Troponin T Values and Post-Operative Outcome in Relatertile Distributi of the P rce tage of Platelet Inhibitory ResponsTable 3 Changes in Troponi T Values nd Post-Operativ OutcTertile Distribution of the Percentage of Platelet Inhibi
Total
(n  99) (
Troponin T (ng/ml)
Baseline 0.02 0.10
12 h post-operatively 0.17 0.46
24 h post-operatively 0.17 0.46
48 h post-operatively 0.12 0.23
Myocardial infarction 6 (6)
Stroke 3 (3)
Renal dysfunction 5 (5)
Prolonged ventilation 48 h 1 (1)
Deep sternal wound infection 2 (2)
Length of stay in the ICU, days 2.7 0.7
Length of post-operative hospitalization, days* 8.8 1.9
alues are mean  SD or n (%). *p  0.05.
ICU  intensive care unit.
Baseline Characteristics and Operative Data AcTable 4 Baseline Characteristics and Opera
Not
(
Age, yrs
Female sex
Body surface area, m2
Hypertension
Diabetes mellitus
Left ventricular ejection fraction, %
Left main disease
Clopidogrel stopped 1 day before surgery*
Thromboelastography parameters
% inhibitory response to clopidogrel
First/second/third tertiles*† 30 (42)/2
% inhibitory response to aspirin
First/second/third tertiles 25 (35)/2
Maximal amplitude, mm 6
Laboratory data
Creatinine, mg/dl
Hematocrit, %
Platelet count, 103/mm2 2
Prothrombin time, s 1
Activated partial thromboplastin time, s 3
Operation time, min 2
Total graft reconstruction time, min
No. of grafts performed*Values are mean  SD or n (%). *p  0.2; these values were further analyzessociated with significantly increased post-operative blood
oss and subsequent transfusion requirement after elective
ultivessel OPCABG. Moreover, only the tertile distribu-
ion of the percentage of platelet inhibitory response to
lopidogrel remained an independent risk factor for trans-
usion requirement, irrespective of the discontinuation date
f antiplatelet therapy.
With increased clinical application of dual antiplatelet
herapy consisting of aspirin and clopidogrel, the potential
emorrhagic complications arising from the use of these
oClopidogrelin Relation to
Response to Clopidogrel
Tertile
–43.4%)
Second Tertile
(43.6%–75.9%)
Third Tertile
(76.5%–100%) p Value
 0.10 0.02 0.05 0.03 0.13 0.805
 0.23 0.12 0.13 0.27 0.74 0.309
 0.13 0.13 0.20 0.28 0.76 0.275
 0.32 0.11 0.14 0.14 0.19 0.894
(9) 2 (6) 1 (3) 0.305
(0) 2 (6) 1 (3) 0.475
(3) 2 (6) 2 (6) 0.576
(3) 0 (0) 0 (0) 0.221
(3) 1 (3) 0 (0) 0.705
 0.6 2.7 0.6 2.8 0.9 0.580
 1.7 8.5 1.9 9.6 2.0 0.007
ng to Transfusion Requirementata According to Transfusion Requirement
fused
2)
Transfused
(n  29) p Value
7 66 7 0.585
) 6 (22) 0.464
0.1 1.7 0.1 0.458
) 16 (59) 0.491
) 11 (41) 1.000
10 62 9 0.682
) 90 (33) 0.811
) 17 (63) 0.118
25 76 19 0.001
)/16 (22) 3 (11)/7 (26)/17 (63) 0.001
20 72 19 0.602
)/3 (32) 8 (30)/9 (33)/10 (37) 0.582
5.9 61.8 5.4 0.762
0.2 1.0 0.2 0.452
3 40 4 0.891
60 253 35 0.506
0.7 11.5 0.7 0.209
3.2 32.1 3.3 0.262
49 267 47 0.700
9 32 11 0.769
0.7 3.6 0.8 0.122ion te toome
tory
First
15.0%
0.02
0.13
0.09
0.11
3
0
1
1
1
2.6
8.2corditive D
Trans
n  7
65
22 (31
1.7
48 (67
30 (42
62
22 (31
32 (44
52
6 (36
69
4 (33
1.4
1.0
40
59
1.3
2.2
71
33
3.3d in the logistic regression analysis; †p  0.05.
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Clopidogrel Responsiveness and Bleeding in OPCABG Surgery December 7, 2010:1994–2002gents in proximity to the CABG have become a major
ssue. Indeed, numerous studies have reported increased
eriprocedure blood loss and the need for transfusion,
emostatic re-exploration, and resource utilization after
ABG in patients with recent exposure to clopidogrel
18–20).
At the same time, it has also become well established that
he platelet inhibitory response to clopidogrel varies sub-
tantially among individuals (10,11). Prospective studies
sing various platelet function monitoring methods have
emonstrated an association between the lack of a pharma-
Predictive Power of Selected Variables for Post-T ansfusion Requirem nt According to L gisticTable 5 Pr dictiv Power of Selected VariabTransfusion Requirement According
Predictors
Un
Odds Rat
Age 1.02 (0.
Female sex 1.54 (0.
Pre-operative hematocrit 1.01 (0.
Left main disease 0.88 (0.
Clopidogrel stopped on the day of surgery 0.47 (0.
% platelet inhibitory response to aspirin
First tertile (13.2%–65.4%) 1.17 (0.
Second tertile (66.1%–77.9%) 1.36 (0.
Third tertile (78.5%–100%) 2.69 (0.
% platelet inhibitory response to clopidogrel
Third tertile (76.5%–100%) 10.63 (2.
No. of grafts performed 1.61 (0.
CI  confidence interval.
Figure 2
Combined Receiver-Operator Characteristic Curve
of the Percentage of Platelet Inhibitory Response to
Clopidogrel for Post-Operative Transfusion Requirement
An area of 0.771 and a p value 0.001 were observed below the line of the
percentage of platelet inhibitory response to clopidogrel with a 95% confidence
interval of 0.647 to 0.868. The optimal cutoff value for post-operative transfu-
sion requirement was 70% platelet inhibitory response to clopidogrel, with a
sensitivity and specificity of 77.8% and 75.0%, respectively.dodynamic effect of clopidogrel and ischemic events after
ercutaneous coronary intervention, which also appears to
ave a dose-response relationship (12–14). These observa-
ions argue against the current uniform approach of drug
essation for 5 (preferably 7) days to patients exposed to
lopidogrel who require surgery. Although no comprehen-
ive data exist, the platelet function assay in this context may
rovide an objective guideline allowing the elimination of
nnecessary delay of surgery while maximizing the ischemic
enefit. By avoiding cardiopulmonary bypass, OPCABG
as been demonstrated to be a significant factor associated
ith reduced transfusion requirement regardless of recent
lopidogrel exposure and has been proposed as an alterna-
ive surgical technique to reduce hemorrhagic complications
6,7,9). Therefore, OPCABG provides an excellent model
ith which to assess the clinical utility of platelet function
ssay when assessing post-operative blood loss and transfu-
ion requirement because it is devoid of a major confound-
ng variable on the coagulation system, cardiopulmonary
ypass (21,22).
As the results of this current study indicate, patients in
he third tertile of the percentage of platelet inhibitory
esponse to clopidogrel had a significantly greater post-
perative blood loss compared with those in the first and
econd tertiles. Consequently, a significantly greater number
f patients in the third tertile of the percentage of platelet
nhibitory response to clopidogrel required transfusion of
acked red blood cells and fresh frozen plasma, and a longer
ength of post-operative hospitalization. Furthermore, pa-
ients in the third tertile of the percentage of platelet
nhibitory response to clopidogrel had an 11-fold increased
isk of requiring transfusion of allogeneic blood products.
lood transfusion in cardiac surgery has been clearly dem-
nstrated to be associated with increased length of hospital
ay, in-hospital mortality, and long-term mortality, espe-
ially after CABG (23,24). In contrast to the results of
revious studies assessing the relationship between clopi-
ativession Analysisor Post-Operative
ogistic Regression Analysis
e Analysis Multivariate Analysis
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f clopidogrel was not associated with increased blood loss
r transfusion requirement in the current trial. Although a
ifferent method of platelet function assay (light transmit-
ance aggregometry) was used in a limited number of
atients (n  45) undergoing CABG, with an emphasis on
he importance of a strict transfusion algorithm, similar
esults had been found in a previous study in which patients
ith clopidogrel-induced platelet inhibition 60% had a
ignificantly greater transfusion requirement (25). The re-
ult that the percentage of platelet inhibitory response to
spirin was not associated with increased blood loss or
ransfusion requirement is also in accordance with the
esults of a previous study demonstrating no influence of
ontinuous aspirin on bleeding complications after either
solated on-pump, off-pump, or repeat CABG (26).
Among the platelet function assays used in clinical
ractice, TEG platelet mapping assay enables quantitative
nalysis of hemostatic status and platelet function as well
27). Although manual pipetting of reagents and a blood
ample are required, it has been demonstrated to be reliable
ith low analytical variation (28). Clinically, it has also been
emonstrated to be able to discriminate patients with
ubsequent ischemic events after percutaneous coronary
ntervention (13). In that study, the percentage of platelet
nhibitory response 30% provided a positive predictive
alue of 73% and negative predictive value of 91% for the
ombined ischemic outcome. In the current study, the TEG
latelet mapping assay could also provide a cutoff value of
he percentage of platelet inhibitory response to clopidogrel
or transfusion requirement after OPCABG by receiver-
perator characteristic curve analysis, which was 70% with a
ensitivity and specificity of 77.8% and 75.0%, respectively.
s patients in the third tertile exhibited significantly in-
reased post-operative blood loss and subsequent transfu-
ion requirement as well as longer post-operative hospital-
zation, TEG platelet mapping assay may provide clinically
seful information concerning the timing of surgery.
Bleeding and subsequent transfusion requirement after
ABG are multifactorial, with potential risk factors includ-
ng age, female sex, chronic renal failure, hemodialysis, poor
eft ventricular ejection fraction, left main disease, and
re-operative anemia (9). Moreover, a recent study demon-
trated that the strongest factor associated with transfusion
as which surgeon performed the CABG (29). Thus, to
alidate the association of platelet inhibitory response to
lopidogrel assessed by a platelet function assay with post-
perative bleeding and transfusion requirement, confound-
ng variables should be controlled as much as possible, as in
he current trial.
tudy limitations. This, in turn, however, invariably con-
ronts generalization of the observed results, which is a
imitation of this study, and the results of this study should
ot be extended to other subsets of patients at increased risk
f bleeding or undergoing on-pump CABG. Another lim-
tation of this study is that, although the statistical power ofhe third tertile as the only independent predictor is suffi-
ient, the introduction of 3 predictors to the multivariate
ogistic regression analysis overfits the model because the
ample size was calculated to validate the primary end points
f this study.
onclusions
egardless of the proximity of clopidogrel exposure, patients
xhibiting a percentage of platelet inhibitory response to
lopidogrel 70% may safely undergo OPCABG without
n increased risk of transfusion requirement. Clinicians are
onfronted with complex decisions regarding the use of dual
ntiplatelet therapy and cessation before surgical revascular-
zation. The findings of the current study might implicate a
otential role of modified TEG in deciding the timing of
PCABG in patients who need continued antiplatelet
herapy without forfeiting the ischemic benefit.
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